Welcome to our dedicated page for ABEONA THERAPEUTICS SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Abeona Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed commercial-stage biopharmaceutical company with common stock traded as ABEO. Recent Form 8-K reports cover operating results, ZEVASKYN commercial launch disclosures, completion of the sale of a Rare Pediatric Disease Priority Review Voucher received after FDA approval of ZEVASKYN, and other material events.
Proxy and governance filings describe annual meeting procedures, board composition, committee assignments, director independence, compensation matters, and amendments to the company’s bylaws. Those bylaws disclosures address stockholder meeting mechanics, virtual meetings, proposal and nomination procedures, quorum requirements, and other Delaware corporate governance provisions.
Abeona Therapeutics SVP and Chief Legal Officer Brendan M. O'Malley sold 12,050 shares of common stock on July 9, 2026 at a weighted average price of $6.9637 per share.
The company notes this sale was made to cover tax obligations from vesting of restricted stock awards. After the sale, O'Malley directly holds 427,953 shares of Abeona Therapeutics common stock.
Abeona Therapeutics Inc. Chief Commercial Officer Madhav Vasanthavada reported an open-market sale of 12,606 shares of common stock at a weighted average price of $6.9637 per share. After this transaction, he directly holds 290,623 shares, indicating that only a small portion of his position was sold.
ABEO filed a Form 144 notice reporting proposed and recent transactions in its Common Stock. The filing lists 141,333 Restricted Stock Awards to be sold on 07/08/2026 and shows prior sales by Vishwas Seshadri of 24,428 shares on 06/08/2026 and 31,916 shares on 06/09/2026, with dollar values recorded alongside each prior sale.
Madhav Vasanthavada has notified plans to sell 12,606 shares of common stock through Stifel Nicolaus & Company on 07/09/2026 on Nasdaq, with an aggregate market value of $87,784.00. These shares relate to restricted stock awards acquired from the issuer on 07/08/2026, alongside prior common stock sales over the past three months.
ABEO submitted a Form 144 disclosing proposed dispositions of Common Stock. The filing lists a 07/08/2026 restricted stock award of 51,733 shares and prior proposed sales on 06/08/2026 and 06/09/2026 totaling 10,271 and 39,067 shares respectively with dollar amounts shown alongside each trade.
ABEO submitted a Form 144 disclosing proposed sales of Common Stock and recent restricted stock award activity. The filing lists 34,230 shares as Restricted Stock Awards dated 07/08/2026 and shows recent sales by Brendan O'Malley of 4,826 shares on 06/08/2026 and 6,305 shares on 06/09/2026. The filing references 56,995,144 shares outstanding as of 07/09/2026.
ABEO filed a Rule 144 notice reporting proposed resale activity in its Common Stock. The notice shows 18,160 shares sold on 06/15/2026 for $103,695.00 and lists a Common Stock outstanding figure of 56,995,144 shares as of 07/06/2026. The securities reported trace to an equity compensation grant dated 05/20/2020.
Abeona Therapeutics director Alland Leila reported an open-market sale of company stock. On this Form 4, Leila sold 11,000 shares of Abeona Therapeutics common stock in a non-derivative, open-market transaction at a weighted average price of $5.917 per share.
The sale occurred through multiple trades on a single day at prices ranging from $5.915 to $5.9334 per share. After these transactions, Leila directly holds 162,614 shares of Abeona Therapeutics common stock.
Abeona Therapeutics Chief Commercial Officer Madhav Vasanthavada reported a routine compensation-related share adjustment. On a Form 4 dated for a transaction on June 16, 2026, 222 shares of common stock at $5.67 per share were withheld to satisfy tax obligations upon vesting of restricted stock awards. Following this withholding, he holds 303,229 common shares directly.
ABEONA THERAPEUTICS INC. director Christine Berni Silverstein reported an open-market sale of 18,160 shares of common stock. The shares were sold at a weighted average price of $5.7101 per share. According to the footnotes, this sale was made to cover tax obligations arising from the vesting of restricted stock awards. After the transaction, she directly owned 119,562 shares of Abeona common stock.